Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,949.00    -78.00 (-2.58%)
Bid:
2,942.00
Ask:
2,946.00
Spread: 4.00 (0.136%)
Market Cap: £4.11b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

29 Jul 2013 07:00

RNS Number : 2528K
Croda International PLC
29 July 2013
 



29 July 2013

 

CRODA INTERNATIONAL PLC

 

Acquisition in China increases emerging market presence and strengthens Performance Technologies business

 

Croda International Plc ("Croda" or "the Group") announces that it has received Chinese regulatory approval to acquire a 65% equity interest in Sichuan Sipo Chemical Co. Ltd ("Sipo"), a non-listed natural speciality chemicals manufacturer based in Mianyang City, Sichuan Province, China. Completion of the transaction is subject to customary closing conditions which are expected to be fulfilled within the next few weeks.

 

The majority stake will be acquired from Sichuan Forever Holding Co. Ltd and certain individual shareholders for a total consideration of £38.2m*, including £8.0m* of debt, subject to working capital, net cash and fixed asset adjustments. Sichuan Forever Holding Co. Ltd will continue as the minority shareholder retaining a 35% equity interest in Sipo.

 

Sipo was established in 1993 and has approximately 300 employees. Sipo makes speciality derivatives from natural raw materials and its products include primary amides, novel fatty acids and speciality esters. In 2012 the business reported a turnover of £28.0m and EBITDA of £3.1m. A state of the art, well invested production facility, custom built in 2011, will provide additional capacity from the outset and increase Croda's proximity to customers in the region, strengthening its existing operations across China and the Group's overall position in Asia. Sipo will also consolidate Croda's global leadership in fatty acid amides and add new technology that will enable the Group to expand its portfolio across a number of its core markets.

 

Apart from a small number of by-products, all of Sipo's products will be sold through the Croda global sales network. Croda's initial focus is to grow sales from its Performance Technologies business to the Polymer Additives and Lubricants sectors, with further opportunities in new markets expected to follow in due course.

 

Steve Foots, Chief Executive of Croda, commented:

 

"This is a significant step forward in our strategy to increase Croda's presence in fast growing and emerging markets. Sipo's manufacturing capabilities together with our marketing expertise and sales force infrastructure are an exciting combination. We will have a stronger platform in niche markets and renewable technologies which will allow us to develop our customer base and drive sales growth in Asia. Our broader footprint in China will also enable us to be more responsive to customer needs in this important region."

 

For further information please contact:

 

Steve Foots, Group Chief Executive

Tel: 01405 860 551

Sean Christie, Group Finance Director

Charles Armitstead / Rosie Oddy, Pendomer Communications

Tel: 020 3603 5224

 

*purchase consideration of RMB361.6m and debt of RMB75.6m at an estimated exchange rate of RMB9.45/£.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQRFMMTMBATBMJ
Date   Source Headline
12th Oct 202311:46 amRNSDirector/PDMR Shareholding
9th Oct 20237:00 amRNSThird Quarter Trading Update
6th Oct 20234:12 pmRNSDirector/PDMR Shareholding
5th Oct 20238:53 amRNSHolding(s) in Company
3rd Oct 20234:03 pmRNSDirector/PDMR Shareholding
27th Sep 20235:17 pmRNSDirector/PDMR Shareholding
26th Sep 202311:38 amRNSDirector/PDMR Shareholding
22nd Sep 20237:00 amRNSDirectorate Change
15th Sep 202311:51 amRNSDirector/PDMR Shareholding
12th Sep 20234:01 pmRNSDirector/PDMR Shareholding
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update
31st May 20232:47 pmRNSDirector/PDMR Shareholding
26th May 20233:51 pmRNSDirector/PDMR Shareholding
11th May 20234:05 pmRNSDirector/PDMR Shareholding
3rd May 20233:08 pmRNSDirector/PDMR Shareholding
3rd May 20233:00 pmRNSDirector/PDMR Shareholding
2nd May 20232:30 pmRNSDirector/PDMR Shareholding
27th Apr 20239:18 amRNSResult of AGM
24th Apr 20234:49 pmRNSDirector/PDMR Shareholding
12th Apr 20232:00 pmRNSDirector/PDMR Shareholding
28th Mar 20233:51 pmRNSDirector/PDMR Shareholding
28th Mar 20233:50 pmRNSDirector/PDMR Shareholding
28th Mar 20233:47 pmRNSDirector/PDMR Shareholding
28th Mar 20233:46 pmRNSDirector/PDMR Shareholding
28th Mar 20233:44 pmRNSDirector/PDMR Shareholding
28th Mar 20233:42 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
27th Mar 20233:52 pmRNSDirector/PDMR Shareholding
27th Mar 20233:48 pmRNSDirector/PDMR Shareholding
24th Mar 202310:57 amRNSDirector/PDMR Shareholding
24th Mar 202310:31 amRNSDirectorate Change
17th Mar 20235:12 pmRNSAnnual Financial Report
17th Mar 20232:30 pmRNSDirector/PDMR Shareholding
17th Mar 202310:53 amRNSDirector/PDMR Shareholding
13th Mar 20232:02 pmRNSDirector/PDMR Shareholding
3rd Mar 202311:57 amRNSDirector/PDMR Shareholding
28th Feb 20239:21 amRNSDirectorate Change
28th Feb 20237:00 amRNSResults for the year ended 31 December 2022
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.